WebApr 11, 2024 · (Albany, USA) DelveInsight's ' Intrahepatic Cholangiocarcinoma Pipeline Insight 2024 ' report provides comprehensive global coverage of available, marketed, and pipeline Intrahepatic Cholangiocarcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline … WebApr 12, 2024 · -- Shanghai Hengrui Medicine, eine Einheit von Jiangsu Hengrui Pharmaceuticals , wird eine klinische Studie für SHR-9839 zur Injektion durchführen, nachdem es die Genehmigung von Chinas National... 13 April 2024
Intrahepatic Cholangiocarcinoma Clinical Trials 2024 (Updates): …
WebNov 21, 2024 · As a leading global China pharmaceutical company with an extensive oncology pipeline and strong integrated capabilities in commercialization, we are very … WebA diverse pipeline built to meet the needs of a diverse patient population 11 pipeline products in various therapeutic categories including oncology, oncology supportive care, … bale kahului maui
HRC LinkedIn
WebPublicly traded on the Shanghai Stock Exchange, Jiangsu Hengrui Medicine boasts over 100 pipelines and products across therapeutic areas such as oncology, metabolics, … WebApr 6, 2024 · The leading STAT Inhibitors Companies include Singh Biotechnology, AndroScience Corporation, Wyeth, Astellas, Dolthera, Jiangsu Hengrui Medicine, Otsuka Pharmaceutica, Daewoong Pharmaceutical,... WebHengrui Europe Biosciences is a biotech start-up based in Zurich, Switzerland, established in 2024. We are a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. and are building a new research center with a differentiated technology platform to support innovative antibody discovery research. Cooperation possibilities bale kahului phone number